Biphenyl

Biphenyl

SCHEMBL2838401

O=C(O)c1c(F)c(F)c(F)c(F)c1F.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
TSHR P16473 1/20 0.46
CDC25B P30305 1/20 0.45
ATM Q13315 1/20 0.45
KMO O15229 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
DHODH Q02127 2/20 0.41
BCL2L1 Q07817 1/20 0.41
BAD Q92934 1/20 0.41
MAPT P10636 1/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10920617 0.87 DHODH (0.47) GAAMEN1KMT2ALMNATP53
SCHEMBL505147 0.86 DHODH (0.45) GAAMEN1KMT2ALMNATP53
SCHEMBL29154298 0.85 DHODH (0.44) GAAMEN1KMT2ALMNAHTT
SCHEMBL27859830 0.85 GAA (0.46) GAAMEN1KMT2ALMNATP53
Toluene SCHEMBL27455697 0.82 MEN1 (0.56) GAAMEN1KMT2ALMNATP53
SCHEMBL203915 0.82 CES2 (0.43) GAAMEN1KMT2ALMNATP53
Biphenyl SCHEMBL2835088 0.81 AKR1C2 (0.47) GAAMEN1KMT2AAKR1C2AKR1C1
SCHEMBL2185510 0.80 CYP3A4 (0.50) GAAMEN1KMT2ALMNATP53
Biphenyl SCHEMBL7938918 0.80 GAA (0.46) GAAMEN1KMT2ALMNATP53
SCHEMBL27819921 0.80 CYP3A4 (0.50) GAAMEN1KMT2ALMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 GAA 990/4885MEN1 2371/4885KMT2A 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.